Omeros Corporation (OMER) slips despite deep earnings beat
Omeros Corporation (OMER) beat third-quarter EPS estimates, but shares slipped as a large GAAP loss and derivative mark-to-market charge overshadowed the results. This deep-dive analysis looks beyond the headline to Yartemlia growth, reimbursement progress, and what the quarter may signal for 2027.
Omeros Corporation (OMER) beat third-quarter 2026 adjusted EPS estimates at $0.06 per share, but the stock fell after investors focused on a $57.4 million GAAP loss driven by a $62.0 million derivative mark-to-market charge. Revenue rose to $41.8 million as Yartemlia continued to scale, with gross sales up 30% sequentially and commercial reach expanding across transplant centers. For investors, the quarter showed improving product momentum, but also highlighted how volatile non-cash accounting items can overwhelm the headline results.
Omeros Corporation (OMER) beat third-quarter 2026 EPS estimates with adjusted earnings of $0.06 per share versus a $0.02 consensus estimate. However, the stock slipped 4.63% to $16.68 in regular trading and fell another 7.97% after hours to $15.35. A $57.4 million GAAP loss, driven largely by a $62.0 million derivative mark-to-market loss, outweighed the commercial progress.
Omeros Corporation (OMER) slips after earnings beat
Key Takeaways
OMER earnings beat on adjusted EPS at $0.06 versus the $0.02 estimate, while revenue of $41.8 million matched the reported $0.04 billion estimate.
Yartemlia remained the main growth engine, producing $35.9 million in net revenue. Gross sales rose 30% sequentially.
The GAAP result was a $57.4 million net loss, or $0.79 per share, because of a $62.0 million non-cash loss tied to the 2029 convertible notes derivative.
Commercial reach expanded to 109 of 175 targeted U.S. transplant centers, while reimbursement support includes an NTAP payment of up to $287,000 per eligible Medicare case.
Management highlighted a January 1, 2027 start for favorable Medicare outpatient reimbursement on 340B-acquired Yartemlia, but gave no specific 2027 revenue target.
The analyst consensus remains Buy, with 1 strong buy, 11 buys, 5 holds, and 2 sells. Cantor Fitzgerald previously upgraded OMER to Overweight with a $22 price target.
The central fact in this Omeros Corporation earnings analysis is the split between operating progress and accounting volatility. Third-quarter revenue reached $41.8 million, up from $32.2 million in the second quarter. Yartemlia generated $35.9 million in net revenue, compared with $28.5 million in the prior quarter. Gross-to-net adjustments increased to 14.0%.
The product is still early in its commercial ramp, yet the trend is moving in the right direction. Yartemlia gross sales grew 30% sequentially, and the company reported wider use across adult transplant centers. Adult patients represented roughly 75% of sales in the second quarter, approaching the historical 85% adult and 15% pediatric mix for U.S. transplant procedures.
Adjusted EPS came in at $0.06, beating the $0.02 consensus estimate. That result also improved from adjusted EPS of $0.02 in the second quarter. However, GAAP EPS fell to negative $0.79 from positive $0.18 in the second quarter and positive $0.78 in the first quarter. The prior fourth quarter produced GAAP EPS of $1.42, while the year-ago quarter posted negative $0.47.
The sharp GAAP swing came from the convertible notes derivative. Omeros recorded a $62.0 million non-cash mark-to-market loss tied to its 2029 notes. That charge does not represent a comparable cash operating expense, but it still dominates the headline income statement. Markets often treat accounting noise as noise until it lands in the earnings headline. Then the distinction becomes less comforting.
The operating numbers provide a cleaner view. Yartemlia revenue grew from $28.5 million to $35.9 million in one quarter, while the product expanded its reach across transplant centers. Still, the earnings history shows that Omeros remains exposed to large quarter-to-quarter swings. The commercial launch is gaining scale, but the GAAP income statement has not settled into a stable pattern.
Reimbursement developments add another layer to the financial picture. Yartemlia received a permanent product-specific J-code effective July 1, and NTAP reimbursement became effective October 1. The company said the NTAP program can provide up to $287,000 in additional Medicare reimbursement for an eligible inpatient treatment. Medicare beneficiaries represent about 30% of U.S. allogeneic transplant recipients.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The market reaction to the OMER earnings call was negative despite the adjusted EPS beat. Shares closed the regular session at $16.68, down 4.63%, on volume of 1,488,309 shares versus an average of 1,333,521. After hours, the stock fell 7.97% to $15.35. The combined move placed the shares about 12.3% below the prior close of $17.49.
The selloff points to a familiar biotech tension. Investors rewarded the Yartemlia launch with operating growth, but they focused on the $57.4 million GAAP loss when judging the quarter. The derivative charge was non-cash, yet its size made the adjusted result harder to appreciate in the short term.
The analyst backdrop remains constructive. OMER carries a Buy consensus, supported by 12 buy or strong-buy ratings against 7 hold or sell ratings. Cantor Fitzgerald upgraded the stock to Overweight on September 22, 2026, with a $22 price target, and maintained that view on October 14.
The post-earnings analyst roundup listed no fresh upgrade or downgrade after the November 16 report. That leaves the pre-earnings Cantor action as the clearest recent rating signal. Its thesis centered on a stronger-than-expected Yartemlia launch, while reimbursement milestones offered additional support for the commercial case.
However, the absence of specific 2027 revenue guidance limits the precision of sell-side models. Analysts can measure current center adoption, sales growth, and reimbursement progress, but the company has not supplied a formal 2027 revenue target in the post-earnings commentary. That gap helps explain why a strong launch metric did not automatically translate into a stronger share price.
Management Commentary
CEO Gregory A. Demopulos framed Yartemlia as more than a single-product launch. The strategy is to change how transplant centers identify TA-TMA, move treatment earlier, and expand the MASP-2 platform into additional diseases. The company is also pursuing a European reexamination after the European Medicines Agency adopted a negative opinion on its marketing application.
"Overall, early commercial indicators, strong transplant center engagement, continued formulary and ordering momentum, and payer alignment with the approved label reinforce our expectation that Yartemlia can become the standard of care for TA-TMA." - Gregory A. Demopulos, Chairman and CEO, earnings call
That statement captures the strategic argument behind the stock. Yartemlia is the first approved treatment for TA-TMA and the first approved inhibitor of the lectin pathway of complement. Omeros is using that position to build relationships with all 175 U.S. transplant centers, expand formulary access, and support earlier diagnosis.
Management also described expansion opportunities in hyperinflammatory acute respiratory distress syndrome, chemotherapy-induced thrombotic microangiopathy, and other transplant-related endothelial injury syndromes. By year end, the company expects enrollment to begin in studies of Yartemlia in hyperinflammatory ARDS and prophylactic treatment for pediatric patients at high risk of severe TA-TMA.
The broader platform adds longer-term optionality. Omeros is advancing OMS1.030, a long-acting MASP-2 antibody, and an oral small-molecule MASP-2 inhibitor for chronic conditions such as membranous nephropathy and neurodegenerative disease. The company also has a collaboration with Novo Nordisk that includes up to $2.1 billion in upfront and milestone payments, plus royalties ranging from the high single digits to the high teens.
"We believe the clinical evidence supports approval, and have requested reexamination." - Gregory A. Demopulos, Chairman and CEO, earnings call
The European regulatory effort matters because approval would widen Yartemlia's commercial reach. At the same time, the negative opinion adds a clear execution risk. The U.S. launch is producing measurable sales, but the next phase depends on continued center adoption, reimbursement execution, and success in expanding the label.
Bottom Line
OMER earnings showed real commercial momentum, with Yartemlia revenue rising to $35.9 million and adjusted EPS beating estimates. Yet the $57.4 million GAAP loss and sharp derivative charge explain why the stock slipped despite the launch progress. For investors, Yartemlia adoption and reimbursement provide the growth case, while accounting volatility and the absence of specific 2027 revenue guidance remain important risks.
+Why did Omeros stock fall after earnings even though OMER beat EPS estimates?
Omeros beat adjusted EPS at $0.06 versus the $0.02 consensus, but investors reacted to a $57.4 million GAAP loss. The loss was driven mainly by a $62.0 million non-cash derivative mark-to-market charge tied to the 2029 convertible notes.
+How much revenue did Omeros Corporation report in Q3 2026?
Omeros reported third-quarter revenue of $41.8 million, up from $32.2 million in the prior quarter. Yartemlia generated $35.9 million in net revenue, compared with $28.5 million in Q2.
+What is driving growth at Omeros (OMER)?
Yartemlia is the main growth engine for Omeros, with gross sales rising 30% sequentially in the quarter. The company also expanded commercial reach to 109 of 175 targeted U.S. transplant centers.
+What reimbursement support does Yartemlia have now?
Yartemlia received a permanent product-specific J-code effective July 1 and NTAP reimbursement effective October 1. Management said the NTAP program can provide up to $287,000 in additional Medicare reimbursement for an eligible inpatient case.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on OMER?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.